Biomerica, Inc. income statement BMRA

Annual Quarterly

In Q1 of fiscal 2027, the quarter ended Aug 31, 2026, Biomerica, Inc. reported revenue of $1.3 million, down 8.3% from the same quarter a year earlier. It recorded a net loss of $1.2 million. The operating loss came to $1.2 million, an operating margin of -97.0%. Diluted earnings per share were -$0.37.

USD in millions, except per-share amounts and margins. The percent under a figure is the change from the same quarter a year earlier.

Line	TTM Aug 31, 2026	Q1 FY2027 Aug 31, 2026	Q4 FY2026 May 31, 2026	Q3 FY2026 Feb 28, 2026	Q2 FY2026 Nov 30, 2025	Q1 FY2026 Aug 31, 2025	Q4 FY2025 May 31, 2025	Q3 FY2025 Feb 28, 2025	Q2 FY2025 Nov 30, 2024
Revenue	4 -11.2%	1 -8.3%	1 +16.8%	1 -11.8%	1 -26.0%	1 -23.6%	1 -32.9%	1 +10.0%	2 +4.4%
Cost of revenue	4 +1.1%	1 +21.5%	1 -4.7%	1 -6.3%	1 -3.3%	1 -37.0%	1 -9.4%	1 -5.7%	1 -3.5%
Gross profit	0 -93.5%	0 -75.7%	-0 +70.9%	-0 -331.6%	0 -88.3%	0 +46.7%	-0 -1320.0%	0 +112.8%	0 +34.5%
Research and development	1 -16.6%	0 -2.8%	0 -18.7%	0 -18.0%	0 -24.9%	0 -28.6%	0 -4.9%	0 -36.7%	0 -37.6%
Selling, general and administrative	5 +2.3%	1 -15.5%	1 +17.7%	1 +6.3%	1 +4.9%	1 -2.2%	1 -16.8%	1 -32.9%	1 -22.9%
Operating expenses	5 -0.9%	1 -13.7%	1 +10.8%	1 +2.0%	1 -0.4%	2 -6.9%	1 -14.7%	1 -33.6%	1 -26.0%
Operating income	-5 -11.1%	-1 -9.7%	-2 +2.0%	-1 -7.3%	-1 -38.3%	-1 +18.3%	-2 -2.4%	-1 +39.5%	-1 +38.2%
Interest income	0 -91.0%	0 -99.9%	—	—	0 +45.0%	1 +1905.4%	0 -78.1%	0 -50.0%	0 -63.3%
Other income (expense)	0 -63.8%	0 -99.9%	0 +1476.0%	-0 -114.0%	0 +45.0%	1 +1905.4%	0 -78.1%	0 -50.0%	0 -63.3%
Pretax income	-5 -36.3%	-1 -24620.0%	-1 +26.0%	-1 -11.7%	-1 -38.0%	0 +100.4%	-2 -8.8%	-1 +39.0%	-1 +36.4%
Income tax	0	0 +100.0%	0 +20.0%	0 +300.0%	0 +266.7%	0 -25.0%	0 -28.6%	-0 -200.0%	-0 -137.5%
Net income	-5 -37.0%	-1 -61700.0%	-1 +25.8%	-1 -12.8%	-1 -38.9%	0 +100.2%	-2 -8.7%	-1 +39.4%	-1 +37.0%
Basic EPS	-1.63 -8.2%	-0.37	-0.37 +47.2%	-0.44 +8.3%	-0.45 -650.0%	0.00 +100.0%	-0.70 -2145.6%	-0.48 -336.4%	-0.06 +33.3%
Diluted EPS	-1.63 -8.2%	-0.37	-0.37 +47.2%	-0.44 +8.3%	-0.45 -650.0%	0.00 +100.0%	-0.70 -2145.6%	-0.48 -336.4%	-0.06 +33.3%
Weighted average shares, basic	3 +26.7%	3 +24.9%	3 +40.4%	3 +25.5%	3 +35.9%	3 +25.5%	2 +105.3%	2 -85.7%	2 -87.3%
Weighted average shares, diluted	3 +26.7%	3 +24.9%	3 +40.4%	3 +25.5%	3 +35.9%	3 +25.5%	2 +105.3%	2 -85.7%	2 -87.3%
Other measures
Depreciation and amortization	0 -16.3%	0 -25.0%	0 -26.1%	0 -4.8%	0 -9.1%	0 -4.8%	0 +4.5%	0 +5.0%	0 -43.6%
EBITDA	-5 -11.6%	-1 -10.4%	-2 +1.6%	-1 -7.5%	-1 -39.3%	-1 +18.5%	-2 -2.3%	-1 +39.9%	-1 +38.1%
Margins
Gross margin	0.95%	8.14%	-8.11%	-4.46%	4.21%	30.72%	-32.58%	1.70%	26.71%
Operating margin	-125.15%	-97.00%	-175.20%	-131.51%	-113.47%	-81.01%	-208.81%	-108.13%	-60.70%
Pretax margin	-114.87%	-96.92%	-130.17%	-132.12%	-108.68%	0.36%	-205.47%	-104.29%	-58.25%
Profit margin	-115.47%	-97.39%	-130.86%	-132.93%	-109.09%	0.14%	-206.14%	-103.93%	-58.07%
EBITDA margin	-123.49%	-95.81%	-173.26%	-129.48%	-111.82%	-79.57%	-205.74%	-106.26%	-59.35%
Effective tax rate	—	—	—	—	—	60.00%	—	—	—

How these figures are calculated

Quarterly columns are single-quarter amounts. When a 10-Q reports only a year-to-date total, as cash flow statements do, the quarter is that total minus the previous quarter's year-to-date total. The fourth quarter is the annual report's full year minus the first nine months. A column marked YTD is a year-to-date total, shown when the earlier report needed for the single quarter is missing. USD in millions, except per-share amounts and margins. Weighted average shares are in millions. Interest expense and finance costs are positive costs. A negative amount on a gain (loss) or income (expense) line is a loss or an expense. EBITDA is operating income plus depreciation and amortization. Interest coverage is operating income divided by interest expense. The first column is the trailing twelve months through the latest quarter. More on our methodology.

New to this? Read How to Read an Income Statement, With a Real Example.

Company profile

Industry: In Vitro & In Vivo Diagnostic Substances (SIC 2835)
Listed as: BMRA (Nasdaq)
Fiscal year ends: May 31
Incorporated in: DE
Headquarters: Irvine, CA
SEC filer status: Non-accelerated filer, Smaller reporting company
SEC CIK: 73290

Other In Vitro & In Vivo Diagnostic Substances companies

All 21 In Vitro & In Vivo Diagnostic Substances companies

Source: SEC EDGAR filings. This is company-reported data, not investment advice.